148 related articles for article (PubMed ID: 2651030)
1. Immunological studies in uremic and kidney transplanted patients.
Langhoff E
Dan Med Bull; 1989 Apr; 36(2):160-75. PubMed ID: 2651030
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Effect of interleukin-2 and methylprednisolone on in vitro transformation of uremic lymphocytes.
Langhoff E; Ladefoged J; Odum N
Int Arch Allergy Appl Immunol; 1986; 81(1):5-11. PubMed ID: 3488966
[TBL] [Abstract][Full Text] [Related]
4. Influence of uremic middle molecules on in vitro stimulated lymphocytes and interleukin-2 production.
Severini G; Diana L; Di Giovannandrea R; Sagliaschi G
ASAIO J; 1996; 42(1):64-7. PubMed ID: 8808461
[TBL] [Abstract][Full Text] [Related]
5. Functional properties of the 50 kd protein associated with the E-receptor on human T lymphocytes: suppression of IL 2 production by anti-p50 monoclonal antibodies.
Tadmori W; Reed JC; Nowell PC; Kamoun M
J Immunol; 1985 Mar; 134(3):1709-16. PubMed ID: 2981919
[TBL] [Abstract][Full Text] [Related]
6. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
Kasid A; Bell GI; Director EP
J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414
[TBL] [Abstract][Full Text] [Related]
7. Immunologic effects of interleukin 2 in primary immunodeficiency diseases.
Flomenberg N; Welte K; Mertelsmann R; Kernan N; Ciobanu N; Venuta S; Feldman S; Kruger G; Kirkpatrick D; Dupont B; O'Reilly R
J Immunol; 1983 Jun; 130(6):2644-50. PubMed ID: 6222111
[TBL] [Abstract][Full Text] [Related]
8. T cells in patients undergoing chronic hemodialysis: mitogenic response, suppressor activity, and interleukin-2 production and receptor generation.
Raskova J; Ghobrial I; Shea SM; Ebert EC; Eisinger RP; Raska K
Diagn Immunol; 1986; 4(4):209-16. PubMed ID: 2944684
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages.
Andersson J; Skansén-Saphir U; Sparrelid E; Andersson U
Clin Exp Immunol; 1996 May; 104 Suppl 1():10-20. PubMed ID: 8625537
[TBL] [Abstract][Full Text] [Related]
10. The role of interleukin-2 in proliferative responses in vitro of T cells from patients after bone marrow transplantation. Evidence that minor defects can lead to in vitro unresponsiveness.
Roosnek EE; Brouwer MC; Vossen JM; Roos MT; Schellekens PT; Zeijlemaker WP; Aarden LA
Transplantation; 1987 Jun; 43(6):855-60. PubMed ID: 3296352
[TBL] [Abstract][Full Text] [Related]
11. Immunologic function of endothelial cells: guinea pig aortic endothelial cells support mitogen-induced T lymphocyte activation, but do not function as antigen-presenting cells.
Roska AK; Johnson AR; Lipsky PE
J Immunol; 1984 Jan; 132(1):136-45. PubMed ID: 6197441
[TBL] [Abstract][Full Text] [Related]
12. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids.
Kam JC; Szefler SJ; Surs W; Sher ER; Leung DY
J Immunol; 1993 Oct; 151(7):3460-6. PubMed ID: 8376786
[TBL] [Abstract][Full Text] [Related]
13. Modulation of T lymphocyte proliferation in mice infected with Schistosoma mansoni: VIP suppresses mitogen- and antigen-induced T cell proliferation possibly by inhibiting IL-2 production.
Metwali A; Blum A; Mathew R; Sandor M; Lynch RG; Weinstock JV
Cell Immunol; 1993 Jun; 149(1):11-23. PubMed ID: 8099848
[TBL] [Abstract][Full Text] [Related]
14. Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape.
Rayman P; Uzzo RG; Kolenko V; Bloom T; Cathcart MK; Molto L; Novick AC; Bukowski RM; Hamilton T; Finke JH
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S81-7. PubMed ID: 10685665
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoids accelerate anti-T cell receptor-induced T cell growth.
Wiegers GJ; Labeur MS; Stec IE; Klinkert WE; Holsboer F; Reul JM
J Immunol; 1995 Aug; 155(4):1893-902. PubMed ID: 7636240
[TBL] [Abstract][Full Text] [Related]
16. Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin 2 production and down-regulation of transferrin receptor expression.
Chouaib S; Welte K; Mertelsmann R; Dupont B
J Immunol; 1985 Aug; 135(2):1172-9. PubMed ID: 2989362
[TBL] [Abstract][Full Text] [Related]
17. Differential glucocorticoid responsiveness of hemodialysis patients' lymphocytes.
Briggs WA; Gao ZH; Xing JJ; Scheel PJ; Burdick JF
ASAIO J; 1997; 43(1):31-4. PubMed ID: 9116350
[TBL] [Abstract][Full Text] [Related]
18. Suppression of dialysis patients' lymphocyte IL-2R expression by glucocorticoids and cyclosporine.
Briggs WA; Gao ZH; Xing JJ; Scheel PJ; Gimenez LF; Samaniego MD; Choi MJ; Burdick JF
Cytokine; 1997 Aug; 9(8):624-8. PubMed ID: 9245491
[TBL] [Abstract][Full Text] [Related]
19. Promotion of human T lymphocyte proliferation by IL-4.
Mitchell LC; Davis LS; Lipsky PE
J Immunol; 1989 Mar; 142(5):1548-57. PubMed ID: 2783946
[TBL] [Abstract][Full Text] [Related]
20. Defective cell-mediated immunity in leprosy: failure of T cells from lepromatous leprosy patients to respond to Mycobacterium leprae is associated with defective expression of interleukin 2 receptors and is not reconstituted by interleukin 2.
Mohagheghpour N; Gelber RH; Larrick JW; Sasaki DT; Brennan PJ; Engleman EG
J Immunol; 1985 Aug; 135(2):1443-9. PubMed ID: 2989366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
